BridgeBio Pharma EPS - Earnings per Share 2018-2025 | BBIO

BridgeBio Pharma annual and quarterly earnings per share history from 2018 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • BridgeBio Pharma EPS for the quarter ending March 31, 2025 was $-0.88, a 340% increase year-over-year.
  • BridgeBio Pharma EPS for the twelve months ending March 31, 2025 was $-3.56, a 10.22% increase year-over-year.
  • BridgeBio Pharma 2024 annual EPS was $-2.88, a 27.09% decline from 2023.
  • BridgeBio Pharma 2023 annual EPS was $-3.95, a 21.17% increase from 2022.
  • BridgeBio Pharma 2022 annual EPS was $-3.26, a 16.41% decline from 2021.
BridgeBio Pharma Annual EPS
2024 $-2.88
2023 $-3.95
2022 $-3.26
2021 $-3.90
2020 $-3.80
2019 $-2.48
2018 $-2.12
2017 $-1.00
BridgeBio Pharma Quarterly EPS
2025-03-31 $-0.88
2024-12-31 $-1.43
2024-09-30 $-0.86
2024-06-30 $-0.39
2024-03-31 $-0.20
2023-12-31 $-0.97
2023-09-30 $-1.08
2023-06-30 $-0.98
2023-03-31 $-0.92
2022-12-31 $-0.91
2022-09-30 $-0.93
2022-06-30 $-0.07
2022-03-31 $-1.35
2021-12-31 $-1.00
2021-09-30 $-1.06
2021-06-30 $-0.66
2021-03-31 $-1.18
2020-12-31 $-1.01
2020-09-30 $-0.98
2020-06-30 $-1.03
2020-03-31 $-0.78
2019-12-31 $-0.60
2019-09-30 $-0.51
2019-06-30 $-0.71
2019-03-31 $-0.66
2018-12-31 $0.00
2018-09-30 $-0.52
2017-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $6.426B $0.222B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.207B 6.94
Dr Reddy's Laboratories (RDY) India $12.054B 21.88
Supernus Pharmaceuticals (SUPN) United States $1.872B 15.19
Bausch Health Cos (BHC) Canada $1.692B 1.25
Amphastar Pharmaceuticals (AMPH) United States $1.181B 7.87
Taysha Gene Therapies (TSHA) United States $0.580B 0.00
Personalis (PSNL) United States $0.437B 0.00
Assembly Biosciences (ASMB) United States $0.103B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00